Saha Cardiovascular Research Center (H.S., S.O.-U., D.Y., M.K.F., J.J.M., D.A.H., A.D., H.S.L.), University of Kentucky, Lexington.
Saha Aortic Center (H.S., A.D., H.S.L.), University of Kentucky, Lexington.
Arterioscler Thromb Vasc Biol. 2022 Oct;42(10):1254-1261. doi: 10.1161/ATVBAHA.122.317712. Epub 2022 Aug 25.
Cross-linking of lysine residues in elastic and collagen fibers is a vital process in aortic development. Inhibition of lysyl oxidase by BAPN (β-aminopropionitrile) leads to thoracic aortopathies in mice. Although the renin-angiotensin system contributes to several types of thoracic aortopathies, it remains unclear whether inhibition of the renin-angiotensin system protects against aortopathy caused by the impairment of elastic fiber/collagen crosslinking.
BAPN (0.5% wt/vol) was started in drinking water to induce aortopathies in male C57BL/6J mice at 4 weeks of age for 4 weeks. Five approaches were used to investigate the impact of the renin-angiotensin system. Bulk RNA sequencing was performed to explore potential molecular mechanisms of BAPN-induced thoracic aortopathies.
Losartan increased plasma renin concentrations significantly, compared with vehicle-infused mice, indicating effective angiotensin II type 1 receptor inhibition. However, losartan did not suppress BAPN-induced aortic rupture and dilatation. Since losartan is a surmountable inhibitor of the renin-angiotensin system, irbesartan, an insurmountable inhibitor, was also tested. Although increased plasma renin concentrations indicated effective inhibition, irbesartan did not ameliorate aortic rupture and dilatation in BAPN-administered mice. Thus, BAPN-induced thoracic aortopathies were refractory to angiotensin II type 1 receptor blockade. Next, we inhibited angiotensin II production by pharmacological or genetic depletion of AGT (angiotensinogen), the unique precursor of angiotensin II. However, neither suppressed BAPN-induced thoracic aortic rupture and dilatation. Aortic RNA sequencing revealed molecular changes during BAPN administration that were distinct from other types of aortopathies in which angiotensin II type 1 receptor inhibition protects against aneurysm formation.
Inhibition of either angiotensin II action or production of the renin-angiotensin system does not attenuate BAPN-induced thoracic aortopathies in mice.
赖氨酸残基在弹性纤维和胶原纤维中的交联是主动脉发育的一个重要过程。BAPN(β-氨基丙腈)抑制赖氨酰氧化酶会导致小鼠出现胸主动脉病变。虽然肾素-血管紧张素系统参与了多种类型的胸主动脉病变,但尚不清楚抑制肾素-血管紧张素系统是否能预防弹性纤维/胶原交联损伤引起的主动脉病变。
4 周龄雄性 C57BL/6J 小鼠饮用含 0.5%wt/vol BAPN 的水,4 周后诱导出现主动脉病变。采用 5 种方法研究肾素-血管紧张素系统的影响。进行批量 RNA 测序以探索 BAPN 诱导的胸主动脉病变的潜在分子机制。
与给予载体的小鼠相比,氯沙坦显著增加了血浆肾素浓度,表明血管紧张素 II 型 1 型受体抑制有效。然而,氯沙坦并没有抑制 BAPN 引起的主动脉破裂和扩张。由于氯沙坦是肾素-血管紧张素系统的可超越抑制剂,因此还测试了不可超越抑制剂厄贝沙坦。尽管血浆肾素浓度升高表明有效抑制,但厄贝沙坦并没有改善 BAPN 给药小鼠的主动脉破裂和扩张。因此,BAPN 诱导的胸主动脉病变对血管紧张素 II 型 1 型受体阻断无反应。接下来,我们通过药理学或基因敲除 AGT(血管紧张素原)抑制血管紧张素 II 的产生,AGT 是血管紧张素 II 的唯一前体。然而,这两种方法都没有抑制 BAPN 诱导的胸主动脉破裂和扩张。主动脉 RNA 测序揭示了 BAPN 给药期间的分子变化,这些变化与其他类型的主动脉病变不同,在这些病变中,血管紧张素 II 型 1 型受体抑制可防止动脉瘤形成。
抑制血管紧张素 II 的作用或肾素-血管紧张素系统的产生都不能减轻 BAPN 诱导的小鼠胸主动脉病变。